We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Beat in Store for Nektar (NKTR) This Earnings Season?
Read MoreHide Full Article
We expect Nektar Therapeutics (NKTR - Free Report) to beat expectations when it reports second-quarter 2019 results on Aug 8, after market close. In the last reported quarter, the company delivered a positive earnings surprise of 4.23%.
While the company surpassed the Zacks Consensus Estimate in three of the last four quarters, it matched the same once, with the average beat being 8.83%.
Shares of the company have lost 13.4% so far this year against the industry’s increase of 7.5%.
Let’s see how things are shaping up for this announcement.
Factors at Play
Nektar earns revenues from proprietary PEGylation material sales to partners and royalties on sales of partnered drugs like AstraZeneca’s Movantik and Takeda’s Adynovate. Royalty revenues displayed an upward trend in the past few quarters and the momentum is likely to continue in the soon-to-be reported quarter.
The company’s lead candidate, bempegaldesleukin (previously NKTR-214; an immuno-stimulatory CD122-biased agonist), is expected to be in focus on the second-quarter earnings call. Nektar has collaborations with multiple drug companies to develop bempegaldesleukin in combination with their cancer candidates including Pfizer’s (PFE - Free Report) Bavencio/ talazoparib or Bavencio/Xtandi. A phase III study is evaluating bempegaldesleukin in combination with Bristol-Myers’ (BMY - Free Report) Opdivo for treating first-line advanced melanoma patients. The company also has a late-stage candidate, Onzeald, which is being developed for pain management. Nektar is also developing NKTR-358 for auto-immune disorders and NKTR-255 for virology indications.
These studies are likely to drive research and development costs higher in the second quarter. Investors will likely focus on the progress of clinical studies, especially bempegaldesleukin, on the second-quarter earnings call.
Nektar’s analgesic candidate, NKTR-181, is under FDA review for treating chronic low back pain in patients new to any opioid therapy. A decision is expected later this month. In May, the company formed a new wholly-owned subsidiary, Inheris Biopharma, which will mainly be responsible for the potential launch and commercialization of NKTR-181.
We expect the company to provide details on the launch plan, following potential approval of NKTR-181 and the path forward for Inheris Biopharma.
Earnings Whispers
Our proven model indicates that Nektar is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 79 cents) and the Zacks Consensus Estimate (loss of 80 cents), stands at +1.43%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Nektar has a Zacks Rank #3. The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here is a biotech stock that you may also want to consider, as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Is a Beat in Store for Nektar (NKTR) This Earnings Season?
We expect Nektar Therapeutics (NKTR - Free Report) to beat expectations when it reports second-quarter 2019 results on Aug 8, after market close. In the last reported quarter, the company delivered a positive earnings surprise of 4.23%.
While the company surpassed the Zacks Consensus Estimate in three of the last four quarters, it matched the same once, with the average beat being 8.83%.
Shares of the company have lost 13.4% so far this year against the industry’s increase of 7.5%.
Let’s see how things are shaping up for this announcement.
Factors at Play
Nektar earns revenues from proprietary PEGylation material sales to partners and royalties on sales of partnered drugs like AstraZeneca’s Movantik and Takeda’s Adynovate. Royalty revenues displayed an upward trend in the past few quarters and the momentum is likely to continue in the soon-to-be reported quarter.
The company’s lead candidate, bempegaldesleukin (previously NKTR-214; an immuno-stimulatory CD122-biased agonist), is expected to be in focus on the second-quarter earnings call. Nektar has collaborations with multiple drug companies to develop bempegaldesleukin in combination with their cancer candidates including Pfizer’s (PFE - Free Report) Bavencio/ talazoparib or Bavencio/Xtandi. A phase III study is evaluating bempegaldesleukin in combination with Bristol-Myers’ (BMY - Free Report) Opdivo for treating first-line advanced melanoma patients. The company also has a late-stage candidate, Onzeald, which is being developed for pain management. Nektar is also developing NKTR-358 for auto-immune disorders and NKTR-255 for virology indications.
These studies are likely to drive research and development costs higher in the second quarter. Investors will likely focus on the progress of clinical studies, especially bempegaldesleukin, on the second-quarter earnings call.
Nektar’s analgesic candidate, NKTR-181, is under FDA review for treating chronic low back pain in patients new to any opioid therapy. A decision is expected later this month. In May, the company formed a new wholly-owned subsidiary, Inheris Biopharma, which will mainly be responsible for the potential launch and commercialization of NKTR-181.
We expect the company to provide details on the launch plan, following potential approval of NKTR-181 and the path forward for Inheris Biopharma.
Earnings Whispers
Our proven model indicates that Nektar is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 79 cents) and the Zacks Consensus Estimate (loss of 80 cents), stands at +1.43%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Nektar has a Zacks Rank #3. The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Nektar Therapeutics Price and Consensus
Nektar Therapeutics price-consensus-chart | Nektar Therapeutics Quote
Another Stock That Warrants a Look
Here is a biotech stock that you may also want to consider, as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) has an Earnings ESP of +3.64% and a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 6. You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>